10-Q: Oncocyte Reports Q1 2025 Results, Revenue Jumps on Pharma Services Growth

Oncocyte Corporation's Q1 2025 net revenue increased significantly due to growth in Pharma Services, while the net loss decreased compared to the same period last year.

Summary

• Oncocyte Corporation reported a net revenue of $2.138 million for the three months ended March 31, 2025, compared to $176,000 for the same period in 2024.
• The increase in revenue is primarily attributed to Pharma Services.
• The net loss for Q1 2025 was $6.671 million, a decrease from the $9.129 million net loss in Q1 2024.
• The company's operating expenses included research and development ($2.924 million), sales and marketing ($1.206 million), and general and administrative expenses ($3.115 million).
• As of March 31, 2025, Oncocyte had cash and cash equivalents of $31.029 million.
• The company completed a private placement and registered direct offering in February 2025, raising approximately $29.1 million in gross proceeds.
• Oncocyte is focusing on commercializing its transplant kitted tests and developing its oncology product line, including DetermaIO.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there is significant revenue growth and a successful capital raise. The focus on commercializing key products and the partnership with Bio-Rad are also positive indicators.

Positives

• Significant increase in net revenue driven by Pharma Services.
• Decrease in net loss compared to the same period last year.
• Successful capital raise of approximately $29.1 million in gross proceeds.
• Focus on commercializing transplant kitted tests and developing the oncology product line.
• GraftAssureCore (Kidney) has received positive coverage and is commercially available.
• Medicare reimbursement confirmed for monitoring certain high-risk patients with GraftAssureCore (Kidney).

Negatives

• The company has incurred operating losses and negative operating cash flows since inception and had an accumulated deficit of $357.2 million as of March 31, 2025.
• Future Pharma Services revenue is expected to be impacted as a result of the shift in strategic focus on commercializing transplant kitted tests.
• The company anticipates that it may continue to incur operating losses and negative operating cash flows for the near future.

Risks

• The inherent uncertainties of developing and commercializing new diagnostic tests for medical use make it impossible to predict the amount of time and expense that will be required to complete the development and commercialization of those tests.
• There is no assurance that the company will be successful in developing new technology or diagnostic tests, nor that any technology or diagnostic tests that it may develop will be proven safe and effective in diagnosis of cancer in humans or will be successfully commercialized.
• Delays in the collaborative arrangement for the development and the commercialization of RUO and IVD kitted transplant products, or delays in obtaining regulatory approval to distribute products for clinical use, or delays in the development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that the company may develop or acquire, could prevent the company from raising sufficient additional capital to finance the completion of development and commercial launch of those tests.
• The company may need to meet significant cash payment or stock obligations to former Insight and Chronix shareholders in connection with the acquisition of those companies, which could cause the company to delay or reduce activities in the development and commercialization of tests.

Future Outlook

Oncocyte expects to continue to incur operating losses and negative operating cash flows for the foreseeable future as it continues the development of its various programs and incurs additional costs associated with being a public company. The company expects to begin commercializing its oncology product line, which includes DetermaIO, over the next 12 months.

Management Comments

• The operating premise is that democratizing access to testing to foster scientific innovation and better treatments ultimately reduces the cost of care, while expanding access and improving outcomes.
• The company believes that combining innovative science with a simple, but disruptive, business model can create enormous value.
• The company believes that the experience of its team with diverse technologies through Pharma Services activities, strong scientific integrity regarding evidence generation and innovation mentality, alongside flexibility in operations and regulatory strategy, will drive success, differentiate the company from its competition, and are foundational to its future.

Industry Context

Oncocyte is operating in the molecular diagnostics market, focusing on organ transplant and oncology. The company's strategy of developing kitted tests aligns with the trend of decentralized testing, empowering local labs and researchers. The company's partnership with Bio-Rad leverages Bio-Rad's ddPCR technology, a key platform in molecular diagnostics.

Comparison to Industry Standards

• The company's focus on molecular diagnostic tests for organ transplant aligns with the growing need for improved transplant monitoring solutions.
• Competitors in the transplant diagnostics space include CareDx and Natera.
• The company's DetermaIO test targets the immuno-oncology market, competing with companies like Roche and Qiagen that offer companion diagnostics for checkpoint inhibitors.
• The company's partnership with Bio-Rad is similar to other collaborations in the diagnostics industry, where companies combine their expertise to develop and commercialize new products.

Legal Proceedings

• The Company received a letter claiming that a recent study regarding the Company's DetermaIO immuno-oncology assay for breast cancer had triggered the Company's first milestone payment obligation under the January 10, 2020 Agreement and Plan of Merger between the Company, Insight Genetics, Inc., and certain other parties.
• The Company strongly disputes the position taken in the letter, believes the arguments to be ill-founded, and intends to vigorously defend its own position.

Related Party Transactions

• Several financing transactions involved related parties, including Broadwood, AWM, Bio-Rad, and certain officers and directors of Oncocyte.
• The company purchased laboratory equipment and incurred laboratory related costs from Bio-Rad.
• The company made finance lease payments under various laboratory equipment leases from Bio-Rad.

Stakeholder Impact

• Shareholders: Dilution may occur from sales of additional equity securities.
• Employees: Severance obligations exist for certain executive officers.
• Customers: Focus on improving patient outcomes through novel diagnostic testing.
• Suppliers: Concentration in the volume of business transacted with Bio-Rad.

Next Steps

• Continue development of GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO and DetermaCNI.
• Pursue a clinical trial in conjunction with the IVD submission in 2025, supporting transplant products.
• Commercialize the oncology product line, including DetermaIO, over the next 12 months.
• Continue to raise additional capital to finance operations.

Key Dates

Keywords

Pharma Services, GraftAssureCore, DetermaIO, Oncocyte, revenue, transplant, oncology, diagnostics, net loss, clinical tests